Discover & Validate Ultrasensitive Fluid, Imaging & Digital Measures to Enable Earlier Intervention, Drive Precision & De-Risk CNS Drug Development
Europe is rapidly becoming a hub for next-generation CNS biomarker innovation. Landmark approvals of the first Alzheimer's blood tests, rapid advances in ultrasensitive biomarker technologies, and growing investment across European biopharma are accelerating the shift towards precision-driven drug development. However, despite this momentum, more than 80% of late-stage CNS clinical trials still fail to meet their primary endpoints, highlighting the urgent need for biomarkers that can improve patient stratification, demonstrate target engagement and generate earlier signals of efficacy.
The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid, imaging and digital biomarkers for CNS drug development. Join 60+ biomarker, translational medicine, neuroscience, precision medicine, bioanalytical, multi-omics, and clinical development leaders from leading to explore how next-generation biomarkers are being discovered, validated and translated across Alzheimer's disease, Parkinson's disease, ALS, epilepsy, schizophrenia, MSA and other CNS indications
Across three days, discover how industry leaders are implementing α-synuclein seed amplification assays, digital cognitive and EEG biomarkers, novel blood-based biomarkers, toxic oligomer assays and multimodal biomarker strategies to strengthen decision-making from early discovery through clinical development. Gain practical insights into harmonising biomarker assays, reducing reliance on lumbar puncture, generating regulatory-ready biomarker data and implementing scalable biomarker programmes that are accelerating the development of CNS therapeutics.
It was a great event with great talks and speakers. Because it was a small event, gave us a great opportunity to network. I enjoyed it and could make great connections.
Senior Scientist, Mass Spectrometry & Neuroscience, Bristol Myers Squibb
This is a new topic to me, so I enjoyed hearing all of the perspectives of the presenters and other participants. I think the workshop day was especially helpful in that respect.
Director, Alnylam Pharmaceuticals
Excellent discussions within smaller, informal setting.
Vice President & Head of Translational Science, Neurology & Oncology, Eisai Co.
*Testimonials from Hanson Wade's Fluid & Imaging Biomarkers in Neuroscience Summit
Attending Companies Include
Explore the Full Three-Day Agenda
- Share with colleagues to plan your attendance
- Preview exclusive industry case studies covering 6+ CNS indications
- Discover the 17+ expert speaker line-up
- View the expected seniority and audience composition
- Explore 8+ hours of in-person networking opportunities
Explore Related Events
Explore the Agenda
Discover the latest case studies and practical strategies shaping the future of CNS biomarker development from Lundbeck, Roche, UCB & more.
Partner With Us
Position your brand alongside Europe's leading biomarker innovators and connect with decision-makers actively seeking new technologies and partners.
Join Biopharma Experts
Exchange ideas with biomarker, translational medicine and clinical development leaders tackling the biggest challenges in neurodegenerative drug development.